Where does Adaptive Biotechnologies's cash flow data come from?

Every line is extracted from Adaptive Biotechnologies's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$49.64M+16.5%	-$59.46M+25.3%	-$79.6M+34.3%	-$121.24M+14.6%	-$141.89M+11.1%
Depreciation and amortization	$15.24M-5.5%	$16.13M-1.5%	$16.39M-1.1%	$16.57M-2.9%	$17.07M-2.7%
Stock-based compensation	$51.26M-0.4%	$51.48M-0.2%	$51.6M-0.5%	$51.86M+0.8%	$51.46M-4.0%
Change in accounts receivable	$4.73M-45.3%	$8.65M+116%	$4M-53.8%	$8.67M+457%	$1.56M-58.4%
Change in inventories	$2.58M+158%	$998K+142%	-$2.39M+56.0%	-$5.44M—	——
Change in accounts payable	——	——	——	——	-$5.05M-853%
Change in other assets	——	——	$1.57M+252%	$447K—	——
Other working capital changes	-$50K+64.8%	-$142K-1,320%	-$10K+23.1%	-$13K+43.5%	-$23K+14.8%
Change in deferred revenue	-$33.07M+18.1%	-$40.4M+4.0%	-$42.09M-168%	-$15.74M-37.4%	-$11.45M-8.9%
Amortization of intangible assets	$1.7M0.0%	$1.7M+0.1%	$1.7M0.0%	$1.7M-0.1%	$1.7M-0.2%
Net cash from operating activities	-$29.09M+39.4%	-$48.04M+20.6%	-$60.53M+24.8%	-$80.47M+5.7%	-$85.34M+10.4%
Capital expenditures	$2.5M-15.6%	$2.96M+23.1%	$2.4M+2.8%	$2.34M-31.5%	$3.41M-6.9%
Net cash from investing activities	——	——	$68.32M+21.3%	$56.33M-4.3%	$58.86M-24.3%
Proceeds from issuance of common stock	$17.45M-2.4%	$17.88M+102%	$8.87M+22.7%	$7.23M+28.0%	$5.65M+2,244%
Net cash from financing activities	$32.45M+6.7%	$30.4M+243%	$8.87M+22.7%	$7.23M+28.0%	$5.65M+2,244%
Net increase (decrease) in cash	$26.93M+20.4%	$22.37M—	——	——	——
Interest paid	$13.85M+9.6%	$12.64M+23.2%	$10.26M+8.3%	$9.48M+5.9%	$8.95M+0.9%
Accretion (Amortization) of Discounts and Premiums, Investments	$1.69M-32.7%	$2.51M-31.8%	$3.68M-28.8%	$5.17M-20.7%	$6.52M-20.5%
Amortization of capitalized software and acquired intangible assets	$1.7M0.0%	$1.7M+0.1%	$1.7M0.0%	$1.7M-0.1%	$1.7M-0.2%
Depreciation	$15.24M-5.5%	$16.13M-1.5%	$16.39M-1.1%	$16.57M-2.9%	$17.07M-2.7%
Impairment Of Long Lived Assets	——	——	——	——	——
Increase Decrease In Operating Lease Right Of Use Assets And Liabilities	-$11.02M-5.4%	-$10.45M+2.9%	-$10.76M-9.5%	-$9.83M-10.8%	-$8.87M+5.5%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	$1.57M+252%	$447K—	——
Inventory write-downs	——	——	——	——	$1.35M-30.2%
Noncash Lease Expense	$5.5M+2.6%	$5.36M+1.5%	$5.28M+1.5%	$5.21M-0.2%	$5.22M-1.1%
Other Noncash Income (Expense)	-$549K+10.1%	-$611K—	——	——	——
Revenue Interest Purchase Agreement Interest	——	——	——	——	-$2.25M+14.2%
Proceeds From Contributed Capital	——	——	——	——	$0—
Accrued payables for capital expenditures	——	——	$1.91M—	——	——
Increase Decrease In Contract With Customer Liability	-$33.07M+18.1%	-$40.4M+4.0%	-$42.09M-168%	-$15.74M-37.4%	-$11.45M-8.9%
Free cash flow	-$30.95M+38.5%	-$50.36M+20.0%	-$62.94M+24.0%	-$82.81M+6.7%	-$88.76M+10.2%
Free cash flow	-$30.95M+38.5%	-$50.36M+20.0%	-$62.94M+24.0%	-$82.81M+6.7%	-$88.76M+10.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Adaptive Biotechnologies's cash flow data come from?: Every line is extracted from Adaptive Biotechnologies's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.